RxDoctor Payments Data

Jennifer Lyons, MD

Ophthalmology · Portland, ORNPI 1629069026

Payments from drug & device makers

$694in general payments, 2019–2025

Across 28 payments — averaging $24.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$318
  • Bausch & Lomb Americas Inc.$72
  • Biotissue Holdings Inc.$72
  • AbbVie$65
  • Sun Pharmaceutical Industries Inc.$40
  • Amgen$30
  • plus $98 from 5 others

What the payments were for

  • Food & beverage$67597%
  • Gifts$193%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$694 in reported general payments places this provider in the 55th percentile of 248 ophthalmology providers in Oregon.

See all ophthalmology providers in Oregon

Medicare billing

Part B allowed, 2024
$297,007
Medicare patients
939
Services billed
2,816

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine75$61,953
LumiganBimatoprost46$30,048
XiidraLifitegrast21$25,029
RocklatanNetarsudil Mesylat/Latanoprost38$23,460
Cyclosporine24$16,301
Brinzolamide42$8,531
Latanoprost537$7,998
VyzultaLatanoprostene Bunod14$5,737
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat211$3,900
Prednisolone Acetate60$3,733
Loteprednol Etabonate17$3,370
Travoprost23$2,755
Fluorometholone19$1,745
Brimonidine Tartrate109$1,590
Carteolol Hcl61$1,510

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$65$92,001121 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$72$30,76635 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 248 ophthalmology providers in Oregon.

Other ophthalmology in Portland

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →